Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the companies said this morning.

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment it’s working on for Dravet syndrome, a rare, debilitating form of epilepsy that affects children.

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, outside the U.S.

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in territories outside the United States,